Startup Congruence discovers misfolded proteins

Startup Congruence discovers misfolded proteins

Montreal, Feb. 10, 2020

Congruence Therapeutics, a biotech working to treat protein diseases through machine learning, has come out of stealth mode with $50 million in funding.

The startup has developed a machine learning-based platform that can identify „misfolded“ proteins associated with diseases such as Alzheimer’s and Parkinson’s.

The process is done entirely through computer modeling. The company’s Revenir platform can not only characterize the protein defects, but also develop compounds to „rescue“ the misfolded cell proteins.

Montreal-based Congruen plans to develop novel small molecules to treat rare diseases „with high unmet medical need.“ The company has not yet revealed which diseases those might be.

The latest Series A funding, led by Fonds de solidarité FTQ and Amplitude Ventures, will go toward building a team of „drug hunters,“ according to CEO Clarissa Desjardins.